Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacodynamics of Unfractionated Heparin vs Comparator in Healthy Subjects
NCT05788913Phase 1Unknown
- Sponsor
- Blau Farmacêutica
- Start
- Jun 2023
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Small Molecules
01
Overview
Phase 1, randomised, open-label trial of heparin in venous thromboembolism (VTE) (2 arms), sponsored by Blau Farmacêutica. Primary endpoints: Maximal Activity (Amax) for Anti-FXa, Area Under the Effect Curve (ASCE0-t) for Anti-FXa and 3 more. Status: unknown.
02
Drugs
heparin
03
Conditions
venous thromboembolism (VTE)
Beyond the preview
Go deeper on NCT05788913.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05788913.